European Innovation Council

VSORA is an intellectual property provider based in France, specializing in digital signal processing (DSP) technology for chipmakers focused on next-generation digital communications systems, particularly 5G networks. Established in 2015 by a team of experienced DSP engineers, the company offers a powerful multi-core DSP architecture that eliminates the necessity for DSP co-processors, thereby enhancing design flexibility. VSORA's innovative DSP development flow enables collaboration between signal processing engineers and software engineers, allowing them to work within the same environment and share source code, which significantly accelerates the time-to-market for new products. The company's mission is to address technical challenges by optimizing DSP computing power while minimizing power consumption and silicon footprint, thereby improving overall system performance.

AMT Medical B.V., founded in 2015 and based in Ede, the Netherlands, specializes in developing innovative devices for heart bypass surgery. The company has created the AMT Heart Bypass System, which utilizes the ELANA bypass technique, originally developed by neurosurgeon Prof. Dr. C.A.F. Tulleken and his team. This minimal invasive approach aims to enhance traditional heart bypass procedures by making them faster, safer, and less invasive, ultimately improving patient outcomes and recovery times. The AMT Heart Bypass System has completed its development and production processes, as well as all pre-clinical trials. A clinical multi-center trial is set to begin in late 2019 or early 2020, marking a significant step in bringing this advanced technology to the medical community.

Sparrow Quantum Aps. is a Danish company specializing in quantum technology, particularly in the development of advanced light-matter interfaces. The firm focuses on creating deterministic single-photon sources, which are essential for various quantum technologies. Sparrow Quantum boasts the highest efficiency for on-chip single-photon sources globally, characterized by exceptional photon purity, indistinguishability, and outcoupling capabilities. This cutting-edge technology is rooted in over twenty years of research at the renowned Niels Bohr Institute in Copenhagen, from which the company holds exclusive licenses for key patents. By leveraging self-assembled quantum dots paired with slow-light photonic-crystal waveguides, Sparrow Quantum enhances light-matter interactions, providing critical advancements for its clients in the field of photonic quantum technology.

Marvel Fusion is a developer of fusion energy technology focused on providing environmentally friendly and safe energy solutions. Founded in 2019 and based in Munich, Bayern, the company specializes in a laser-based nuclear fusion reactor that utilizes short pulse, high energy, and electrically efficient lasers. This technology aims to commercialize baseload fusion electrical power, enabling consumers to access clean, safe, and reliable energy sources.

Stablepharma Ltd specializes in developing innovative processes for vaccine stabilization, focusing on its technology platform, StablevaX™, which transforms existing approved vaccines, therapeutics, and diagnostics into thermostable products that do not require refrigeration. This advancement addresses the global challenges associated with cold chain logistics, allowing for efficient and waste-free vaccine delivery. The company has identified up to 60 vaccine candidates suitable for its technology and collaborates with global vaccine manufacturers, academic institutions, and non-governmental organizations to enhance its pipeline of thermostable products. Founded in 2012 and based in Bath, United Kingdom, Stablepharma aims to reduce costs and carbon emissions while expanding access to vaccines for both children and adults.

Wooptix S.L., founded in 2014 and headquartered in Madrid, Spain, specializes in advanced imaging technologies. The company develops light field and wavefront phase imaging software that captures comprehensive information about light, utilizing the full resolution of sensors. This innovative platform allows for three-dimensional modulation of images across various camera setups, producing volumetric images and videos with enhanced data points and high frame rates. By focusing on improving human interaction with the environment, Wooptix aims to redefine the way users perceive and engage with their surroundings, offering new possibilities for image quality and post-processing capabilities.

QDI Systems B.V. is a startup based in Groningen, the Netherlands, specializing in the development of advanced imaging devices for medical applications using quantum dot technology. The company focuses on creating X-ray sensors that deliver high-contrast and high-resolution mammograms, allowing for improved diagnostic capabilities while minimizing radiation exposure for patients. QDI Systems emphasizes user-friendliness by providing accessible quantum dot materials along with comprehensive instructions for constructing high-performance imaging devices. This approach enables healthcare professionals to obtain precise medical images, enhancing the overall efficacy of diagnostic procedures.

QDI Systems B.V. is a startup based in Groningen, the Netherlands, specializing in the development of advanced imaging devices for medical applications using quantum dot technology. The company focuses on creating X-ray sensors that deliver high-contrast and high-resolution mammograms, allowing for improved diagnostic capabilities while minimizing radiation exposure for patients. QDI Systems emphasizes user-friendliness by providing accessible quantum dot materials along with comprehensive instructions for constructing high-performance imaging devices. This approach enables healthcare professionals to obtain precise medical images, enhancing the overall efficacy of diagnostic procedures.

Photon IP is a deeptech startup located in Eindhoven, the Netherlands, focused on developing advanced technologies for photonics applications. The company specializes in application-specific semiconductors that cater to various sectors, including wearable electronics and data centers. By providing innovative solutions, Photon IP supports clients in industries such as automotive and telecommunications, aiming to enhance the functionality and efficiency of their products.

GBM Works B.V., founded in 2016 and headquartered in The Hague, Netherlands, specializes in the installation of offshore wind turbine foundations. The company has developed an innovative method known as the GBM Vibro-drill, which aims to minimize ocean noise during the installation process. This technology not only enhances the efficiency of installing turbine foundations but also addresses environmental concerns by reducing disruption to marine ecosystems and nearby communities. Through its advancements, GBM Works contributes to the growth of the renewable energy sector, facilitating the expansion of offshore operations in a sustainable manner.

Onward is developing an Implantable Neuro-stimulation System (INS) with real-time motion feedback and uses training tools to rehabilitate patients suffering from neurological disorders such as spinal cord injury (SCI).

INBRAIN Neuroelectronics is a medical device company based in Barcelona, Spain, that specializes in developing graphene-based neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. Founded in 2019, the company offers the world's first brain-computer interface (BCI) therapeutics platform, which integrates precise BCI decoding with micrometric modulation to provide adaptive and personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. Its technology enables continuous real-time monitoring and autonomous adjustments to therapy, enhancing therapeutic outcomes while reducing side effects. INBRAIN is also engaged in strategic collaborations, including with Merck KGaA, to expand its innovative solutions into peripheral nerve and systemic disease applications, thereby advancing the field of neurotechnology and bioelectronics.

Maynooth University is internationally recognised for quality and value of Their research and scholarship and Their dedication and commitment to teaching and Their students. Part of the NUI and formally established as an autonomous university in 1997, Maynooth University traces its origins to the foundation of the Royal College of St. Patrick in 1795, drawing inspiration from a heritage that includes over 200 years of education and scholarship. The University is a place of lively contrasts. It is a modern institution, dynamic, rapidly-growing, research-led and engaged, yet grounded in historic academic strengths and scholarly traditions.

Axelera AI focuses on providing specialized hardware and software platforms to enhance artificial intelligence tasks, particularly in edge computing. Its primary product, the Metis™ AI Platform, combines hardware and software to offer high-performance, energy-efficient AI inference solutions. The platform's innovative design has earned recognition as a CES® 2024 Innovation Awards Honoree. Established in 2021 after incubation by Bitfury and collaboration with imec, Axelera AI is headquartered in the AI Innovation Center at the High Tech Campus in Eindhoven, with research and development offices in Belgium, Switzerland, and Italy. The company's team comprises experts in AI from leading firms and Fortune 500 companies, focusing on delivering sustainable edge applications through a custom dataflow architecture and multicore in-memory computing that minimizes power consumption.

Qblox is a Dutch scaleup focused on quantum technology, specializing in the development of control hardware for quantum computers. The company offers patented, modular control systems that integrate hardware and software solutions designed to enhance the management of qubits. By creating a distributed processor architecture, Qblox simplifies experimental setups while improving gate fidelities through advanced electronics that reduce noise and drift. This innovation enables scientists to minimize crosstalk, implement low-latency control flows, and optimize measurement efficiency, addressing significant scientific and engineering challenges in the evolution of quantum computing. Qblox aims to support the transition from prototype quantum computers to powerful computational systems, thereby contributing to the broader advancement of quantum technology.

King's College London (informally King's or KCL) is a public research university located in London, United Kingdom, and a constituent college of the federal University of London. King's is arguably the third-oldest university in England, having been founded by King George IV and the Duke of Wellington in 1829, receiving its royal charter in the same year. St Thomas' Hospital, which is now a teaching hospital of King's College London School of Medicine, has roots dating back to 1173. In 1836, King's became one of the two founding colleges of the University of London. King's is based in the centre of London and organised into nine academic schools, spread across four Thames-side campuses in central London and another in Denmark Hill in south London. It is one of the largest centres for graduate and post-graduate medical teaching and biomedical research in Europe; it is home to six Medical Research Council centres for <a href="https://www.dissertationcorp.co.uk/">dissertation help</a> , the most of any British university, and is a founding member of the King's Health Partners academic health sciences centre. King's has around 25,000 students and 6,113 staff and had a total income of £587 million in 2012/13, of which £164 million was from research grants and contracts. King's is a world-leading university, currently ranked 19th in the world (6th in the UK and 8th in Europe) in the 2013 QS World University Rankings, and 38th in the world (6th in the UK and 9th in Europe) in the 2013 Times Higher Education World University Rankings. There are currently 12 Nobel Prize laureates amongst King's alumni and current and former faculty. King's is a member of the Association of Commonwealth Universities, the European University Association, the Russell Group and Universities UK. It forms part of the 'golden triangle' of British universities.

Tilkal is a Paris-based company founded in 2017 that specializes in supply chain traceability through its innovative software platform. This platform utilizes a B2B blockchain network to facilitate secure and verifiable data sharing among various supply chain stakeholders. Tilkal’s software captures traceability data from physical products in a ledger, enabling companies to obtain real-time insights into their supply chains. Customers leverage the platform to address critical questions regarding product location, sourcing risks, ESG commitments, and compliance verification. Notable clients include Danone, Daher, Joone, and the Responsible Mica Initiative, among others. The Tilkal network comprises over 70 independent nodes, with nearly 700 companies actively participating to share and analyze data, thereby enhancing the resilience, sustainability, and ethical standards of their supply chains.

e-peas SA is a Belgian company that specializes in designing and manufacturing electronic systems that enable energy autonomy for Internet of Things (IoT) applications. Founded in 2014 and based in Mont-Saint-Guibert, the company develops energy harvesting solutions that allow IoT devices to draw power from their environment, including sources such as solar, thermal, vibration, and radiofrequency. e-peas produces energy harvesting power management integrated circuits (PMICs) and low-power microcontrollers that enhance the performance and longevity of batteries in connected devices. By facilitating the efficient use of ambient energy, e-peas aims to reduce the need for frequent battery replacements across various sectors, including home automation, healthcare, and agriculture. The company's innovations contribute to making IoT devices smarter and more energy-efficient, ultimately striving for a future where devices can operate indefinitely without traditional power sources.

Ability Pharmaceuticals is a drug discovery and development company based in Barcelona, Spain. It develops human therapeutics targeting cell membranes to treat cancer and other indications with unmet medical needs. Ability Pharmaceuticals is focused on developing new drugs for the treatment of lung cancer and pancreatic cancer. The company develops Lipid Analogue Therapeutics, a new drug class that modifies the composition of the cell membrane and displays a capacity to influence the local organization of lipid structures in the cell membrane, inducing the formation of non-lamellar phase structures. Its development pipeline includes ABTL0812 product in preclinical development; and ABTL1014, a drug candidate in preclinical characterization.

Multiverse Computing SL is a software development company based in San Sebastian, Spain, with an additional office in Toronto, Canada. Founded in 2019, the company specializes in creating quantum computing software that addresses complex financial and macro-economic challenges. Its products are tailored for various applications, including portfolio optimization, risk analysis, and market simulation. By leveraging probabilistic and nondeterministic technologies, Multiverse Computing aims to help organizations across diverse sectors such as banking, energy, manufacturing, and logistics navigate the complexities of the second quantum revolution, ultimately providing them with a competitive advantage in their respective industries.

Daze is an engineering startup focused on creating innovative solutions for electric vehicle charging. Its flagship product, DazePlug, is an automatic charging device that utilizes smart charging ecosystems and energy management systems. This technology enables automatic inductive charging, significantly reducing the time required to charge electric vehicles while eliminating the need for manual handling of cables. DazePlug features a retrofit design that is both waterproof and dustproof, ensuring durability and ease of use. By simplifying the charging process, Daze aims to enhance user experience and convenience for electric vehicle owners.

Palobiofarma is a Spanish biotechnology company based in Barcelona's Science Park, dedicated to the discovery and development of new drugs that target adenosine receptors. The company aims to be a leader in adenosine drug discovery in Europe by focusing on innovative therapies. Palobiofarma specializes in creating selective adenosine receptor modulators, with a particular emphasis on addressing advanced prostate cancer. By leveraging medicinal chemistry and in vitro pharmacology, the company is working towards bringing its first marketed drug to the medical community, supporting healthcare professionals in their efforts to treat this challenging disease.

NETRIS Pharma S.A.S. is a biotechnology company based in Lyon, France, that specializes in identifying and developing therapeutic molecules aimed at treating cancer. The company's innovative approach focuses on targeting dependence receptors, which are trans-membrane proteins that play a crucial role in signaling within cells and regulating tumor development. NETRIS Pharma offers both in vitro and in vivo research services, along with preclinical practices, to advance drug manufacturing for various types of cancer, including breast cancer, lung cancer, glioblastoma, and neuroblastoma. Founded in 2008, the company is dedicated to contributing to the pharmaceutical industry by developing novel cancer therapies.

Antabio is a private biopharmaceutical company based in Labege, France, focused on developing novel treatments for drug-resistant infections, particularly targeting critical priority pathogens. Founded in 2009, the company specializes in creating antibacterial resistance-breakers that can restore the efficacy of existing antibiotics. Its key innovation includes inhibitors of bacterial metalloenzymes, specifically Metallo ß-lactamases (MBLs), which are designed to be used in combination with carbapenems to address significant treatment gaps in drug-resistant nosocomial infections. Antabio aims to provide health professionals with effective medicinal products to combat life-threatening respiratory infections, including carbapenem-resistant pneumonia and chronic pulmonary diseases. The company has received recognition for its research efforts, including a Wellcome Trust Seeding Drug Discovery Award.

Ignion is an antenna innovator based in Sant Cugat del Vallès, Spain, founded in 2015. The company specializes in manufacturing multiband, multipurpose antennas that cater to mobile and wireless connectivity requirements. Its product offerings include ready-to-use antennas designed for Internet of Things applications and short-range wireless devices, particularly suited for indoor environments. Ignion's solutions allow clients to seamlessly integrate these antennas into their industrial designs, facilitating efficient connectivity in various applications.

ResoTher Pharma is a Copenhagen-based biotechnology company specializing in the development of peptide-based drugs aimed at treating cardiovascular and inflammatory disorders characterized by neutrophil-driven inflammation. The company focuses on leveraging the endogenous immunomodulator Annexin A1 to create therapeutic solutions that act as resolution therapy for diseases associated with innate immune activation. By targeting a specific G-protein coupled receptor on leukocytes, ResoTher Pharma's patented peptide drugs aim to mimic the body's natural mechanisms for resolving inflammation and promoting tissue healing, addressing significant unmet medical needs in the treatment of these conditions.

VSORA is an intellectual property provider based in France, specializing in digital signal processing (DSP) technology for chipmakers focused on next-generation digital communications systems, particularly 5G networks. Established in 2015 by a team of experienced DSP engineers, the company offers a powerful multi-core DSP architecture that eliminates the necessity for DSP co-processors, thereby enhancing design flexibility. VSORA's innovative DSP development flow enables collaboration between signal processing engineers and software engineers, allowing them to work within the same environment and share source code, which significantly accelerates the time-to-market for new products. The company's mission is to address technical challenges by optimizing DSP computing power while minimizing power consumption and silicon footprint, thereby improving overall system performance.

SolasCure Limited is a biotechnology company based in Wales, United Kingdom, focused on developing innovative solutions for patients with chronic wounds. Founded in 2017, the company is advancing its product Aurase, a hydrogel designed to facilitate wound debridement by removing dead, damaged, or infected tissue to enhance healing. Aurase incorporates a recombinant enzyme derived from maggots, leveraging biomimicry and evidence-based medicine to improve wound care outcomes. SolasCure aims to provide effective wound bed preparation across various healthcare settings, ultimately accelerating the healing process for individuals suffering from chronic wounds.

FarmInsect GmbH, founded in 2019 and based in Bergkirchen, Germany, specializes in automated insect breeding systems designed to provide a sustainable and efficient source of animal feed. The company focuses on enabling local farmers to produce insect larvae from organic residues, which can be used as protein feed for livestock such as chickens, pigs, and fish. By offering a solution that replaces imported soy and fishmeal with locally sourced insect protein, FarmInsect aims to enhance the sustainability of animal husbandry while ensuring that farmers have a consistent supply of young larvae each week for their feeding needs.

Nanogence SA, established in 2017 and located in Renens, Switzerland, specializes in the development of innovative material solutions for the construction industry. The company focuses on creating synthetic, tailor-made materials that enhance the performance and sustainability of construction applications, including cement and concrete. By leveraging advanced knowledge in chemistry, material science, and nanotechnology, Nanogence has developed patented additive formulations that significantly improve the binding efficiency of cement and concrete while reducing carbon emissions by up to 50%. This enables manufacturers to achieve valuable cost savings, enhance durability, and contribute to more sustainable construction practices in a rapidly growing global market.

Epigene Labs SAS, founded in 2019 and headquartered in Paris, France, with an additional office in Boston, Massachusetts, develops a biotechnology platform that harnesses advanced artificial intelligence to transform genomic data into actionable insights for precision oncology. The platform addresses the challenges of aggregating, analyzing, and visualizing extensive genomic datasets, which are crucial for advancing precision oncology. By integrating proprietary data from partners with publicly available information, Epigene Labs provides medical researchers with user-friendly analytics and insights that facilitate drug development and research in cancer treatment. The company focuses on forming value-based partnerships with leading cancer centers and prominent biotech firms to enhance the efficacy of oncology solutions.

Swisspod Technologies SA is a transport development firm based in Monthey, Switzerland, founded in 2019. The company focuses on designing and developing Hyperloop vessels, which are tube-based transportation systems aimed at providing sustainable and efficient high-speed travel. Swisspod leverages high-quality Swiss engineering to create fully-electric Hyperloop pods that promise scalable and rapid transit between distant cities. The firm emphasizes energy efficiency and economic viability in its innovations, making its capsules both affordable and environmentally friendly. With a team of multidisciplinary experts, Swisspod is dedicated to transforming high-speed travel through its cutting-edge technology.

Microsure is a medical device company based in Eindhoven, The Netherlands, founded in 2014. It specializes in developing innovative solutions for microsurgery, a field that operates at the limits of physical capabilities. The company's flagship product is a motion stabilizer system designed specifically for microsurgeons, which enhances surgical precision by filtering out tremors and providing exceptional control during procedures. This technology allows for hybrid microsurgical procedures that enable surgeons to utilize their own instruments, thereby reducing costs for hospitals. The Microsure motion stabilizer has demonstrated its effectiveness in clinical trials, including successful operations for lymphedema. By improving the quality of microsurgical procedures, the company aims to expand treatment options for patients and facilitate the development of new, highly accurate surgical techniques.

Xeltis AG, established in 2006, is a clinical-stage medical device company based in Zurich, Switzerland, with additional operations in the Netherlands and the USA. The company specializes in developing bio-absorbable heart valves and blood vessels, utilizing a proprietary polymer-based technology called RestoreX. This technology enables the patient's natural healing system to develop tissue that permeates the heart valve, forming a new functional valve within it through a therapeutic approach called Endogenous Tissue Restoration (ETR). Xeltis' restorative devices include implantable small diameter blood vessels for hemodialysis vascular access and coronary artery bypass graft (CABG) surgery, as well as pulmonary heart valves, with ongoing clinical trials. The company has secured significant funding from investors such as EQT Life Sciences, Kurma Partners, and the European Investment Bank, totaling over €30 million.

INBRAIN Neuroelectronics is a medical device company based in Barcelona, Spain, that specializes in developing graphene-based neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. Founded in 2019, the company offers the world's first brain-computer interface (BCI) therapeutics platform, which integrates precise BCI decoding with micrometric modulation to provide adaptive and personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. Its technology enables continuous real-time monitoring and autonomous adjustments to therapy, enhancing therapeutic outcomes while reducing side effects. INBRAIN is also engaged in strategic collaborations, including with Merck KGaA, to expand its innovative solutions into peripheral nerve and systemic disease applications, thereby advancing the field of neurotechnology and bioelectronics.

Creating transformative change in urban mobility, making our cities cleaner and more enjoyable. We first focus on urban logistics, moving goods around the city in ways that are sustainable, efficient and cost-effective. Our vehicle and its modular platform system, with easily swappable modular units, meets the needs of city logistics. From moving food to flowers to furniture, the possibilities are endless. ONO’s founders, pioneer in e-mobility solutions, Beres Seelbach, former head of design at Mercedes and Volkswagen, Murat Günak, and light electric vehicle expert and engineer, Philipp Kahle, sought to rethink and reshape modern urban transportation. They put together a forward-thinking group of designers, engineers and creative thinkers who shared their vision of transforming urban mobility. ONO is a Berlin-based e-mobility company introducing a whole new category of emissions-free vehicle: the Pedal Assisted Transporter (PAT), combining the flexibility of a bicycle with the capacity and durability of a van. We offer environmentally friendly urban logistics solutions designed and optimised for cities of today.

Scipio Bioscience is a biotechnology company based in Paris, France, founded in 2017. The company specializes in manufacturing benchtop kits that provide a sample preparation solution for single-cell studies. These kits are designed for use in sequencing applications within both clinical and basic research, particularly in the field of transcriptomics. Scipio Bioscience's innovative products enable research laboratories to perform single-cell barcoding in a test tube format, facilitating advanced analysis and research in the life sciences.

Wooptix S.L., founded in 2014 and headquartered in Madrid, Spain, specializes in advanced imaging technologies. The company develops light field and wavefront phase imaging software that captures comprehensive information about light, utilizing the full resolution of sensors. This innovative platform allows for three-dimensional modulation of images across various camera setups, producing volumetric images and videos with enhanced data points and high frame rates. By focusing on improving human interaction with the environment, Wooptix aims to redefine the way users perceive and engage with their surroundings, offering new possibilities for image quality and post-processing capabilities.

Wooptix S.L., founded in 2014 and headquartered in Madrid, Spain, specializes in advanced imaging technologies. The company develops light field and wavefront phase imaging software that captures comprehensive information about light, utilizing the full resolution of sensors. This innovative platform allows for three-dimensional modulation of images across various camera setups, producing volumetric images and videos with enhanced data points and high frame rates. By focusing on improving human interaction with the environment, Wooptix aims to redefine the way users perceive and engage with their surroundings, offering new possibilities for image quality and post-processing capabilities.

ADmit Therapeutics, S.L. is a biotechnology company focused on developing diagnostic tests for the early detection of Alzheimer's disease. Established in 2017 and based in Begues, Spain, the company utilizes an epigenetic analysis of blood samples to identify mitochondrial biomarkers, which are not related to traditional indicators such as ß-amyloid or tau proteins. The test employs next-generation sequencing to analyze various methylcytosines in mitochondrial DNA, providing medical practitioners with an accessible method for detecting early-stage Alzheimer's. This innovative approach not only aids in diagnosis but also supports pharmaceutical companies in accelerating the identification of potential curative treatments.

Plasmacure is a Netherlands-based company that specializes in developing cold plasma technology aimed at treating chronic wounds, particularly diabetic foot wounds. Their patented solution effectively kills bacteria, stimulates cell proliferation, and enhances microcirculation, which helps reduce the risk of amputation. By addressing these critical aspects of wound healing, Plasmacure's technology aims to improve the quality of life for patients suffering from chronic wounds.

EBAMed SA is a Swiss startup based in Geneva, established in 2018, that focuses on developing innovative medical technology for treating heart arrhythmias. The company is working on an ultrasound-based device designed to monitor heart motion and facilitate non-invasive ablation therapy using proton beams. This technology aims to provide a safe and effective alternative for patients by allowing real-time synchronization of proton therapy with heart movement. By integrating both hardware and software components, EBAMed's device enhances treatment capabilities for existing proton therapy centers, enabling them to offer advanced, non-invasive treatment options for cardiac patients in an outpatient setting.

TreaTech is a Swiss Cleantech company founded in 2015 by engineers from the École Polytechnique Fédérale de Lausanne (EPFL). The company focuses on developing innovative treatment technology aimed at addressing the challenges of wastewater management. Its catalytic hydrothermal gasification (HTG) system provides an eco-friendly solution for the disposal of various liquid wastes, such as sewage sludge, which are typically incinerated or sent to landfills. This advanced thermochemical process transforms these wastes into valuable by-products, including renewable gas, clean water, and mineral salts that can be further upgraded into fertilizers. TreaTech's approach aligns with sustainable development goals and the principles of a circular economy, enabling clients to benefit from efficient wastewater treatment while recycling essential resources.

Sparrow Quantum Aps. is a Danish company specializing in quantum technology, particularly in the development of advanced light-matter interfaces. The firm focuses on creating deterministic single-photon sources, which are essential for various quantum technologies. Sparrow Quantum boasts the highest efficiency for on-chip single-photon sources globally, characterized by exceptional photon purity, indistinguishability, and outcoupling capabilities. This cutting-edge technology is rooted in over twenty years of research at the renowned Niels Bohr Institute in Copenhagen, from which the company holds exclusive licenses for key patents. By leveraging self-assembled quantum dots paired with slow-light photonic-crystal waveguides, Sparrow Quantum enhances light-matter interactions, providing critical advancements for its clients in the field of photonic quantum technology.

Naco Technologies Ltd, established in 2009 and headquartered in Riga, Latvia, specializes in the development, manufacturing, and supply of nano-coating technologies. The company offers a range of high-performance, multilayer and multicomponent coatings designed to enhance the durability and efficiency of equipment across various industries, including tooling, automotive, aerospace, and micro-chip manufacturing. These coatings, which include oil-enhanced, wear-protective, thermal barrier, and liquid-repellent varieties, are applied to client-supplied parts, creating ready-to-use coated components. In 2015, Naco Technologies was acquired by the Germany-based Schaeffler Group, further expanding its global reach and resources.

Bluedrop Medical, established in 2014 and headquartered in Galway, Ireland, specializes in the development, manufacturing, and commercialization of an IoT-enabled device for early detection of diabetic foot ulcers. Their home-based system scans patients' feet daily, transmitting data to the cloud for analysis via advanced algorithms, which can identify skin abnormalities. This innovative solution aims to reduce the risk of amputation and improve the lives of diabetic patients, with a significant potential market given that up to 25% of diabetics may develop foot ulcers.

Samplix is a biotechnology company based in Herlev, Denmark, focused on single-molecule sample preparation for DNA and RNA. It has developed the Xdrop™ technology, which utilizes a unique “water-oil-water” droplet system to create millions of reaction chambers for handling individual DNA molecules. This innovative approach allows for targeted enrichment of large DNA fragments and enables researchers to sequence specific genetic regions effectively. Samplix's technology addresses the limitations of existing multi-molecule preparation methods, providing enhanced precision and sensitivity while simplifying the sample preparation process. Its solutions empower scientists to make informed research decisions, particularly in applications related to virus integration and CRISPR editing.

Nemysis Limited is a specialty pharmaceutical company based in Dublin, Ireland, founded in 2005. The company focuses on addressing unmet needs in nutritional disorders and deficiencies through a staged approach to product development. Nemysis manufactures food supplements, medical matrix products, and prescription items, targeting the same conditions across different market segments. Among its innovative offerings are a gastric and trypsin-resistant glutenous product for oral enzymatic therapy aimed at celiac disease patients, as well as an iron supplement designed to minimize gastrointestinal side effects associated with iron supplementation. Additionally, the company is developing a glutenous medical device that effectively destroys gluten, helping to prevent symptoms in individuals with celiac disease and non-celiac gluten sensitivity.

nyris GmbH is a Berlin-based company that specializes in a visual product search platform, catering to various industries such as retail, e-commerce, industrial, manufacturing, media, entertainment, and financial services. Established in 2015, nyris focuses on providing a more intuitive search experience by allowing users to find products and objects in images and videos through advanced technologies like artificial intelligence and neural networks. This platform is designed to enhance efficiency by delivering search results in under one second, thereby reducing the friction often associated with traditional text-based searches. With a presence in over 50 countries, nyris serves a diverse clientele, enabling them to improve discovery and operational processes. The company is backed by notable investors, including eCapital, IKEA, and Axel Springer.

Samplix is a biotechnology company based in Herlev, Denmark, focused on single-molecule sample preparation for DNA and RNA. It has developed the Xdrop™ technology, which utilizes a unique “water-oil-water” droplet system to create millions of reaction chambers for handling individual DNA molecules. This innovative approach allows for targeted enrichment of large DNA fragments and enables researchers to sequence specific genetic regions effectively. Samplix's technology addresses the limitations of existing multi-molecule preparation methods, providing enhanced precision and sensitivity while simplifying the sample preparation process. Its solutions empower scientists to make informed research decisions, particularly in applications related to virus integration and CRISPR editing.

Wingtra AG, founded in 2014 and based in Zürich, Switzerland, specializes in the manufacture of professional drones, notably the WingtraOne, a vertical take-off and landing (VTOL) UAV. This drone is designed for high-precision data collection and has applications across various industries, including surveying, agriculture, forestry, and infrastructure management. Since its market introduction in 2017, Wingtra has established partnerships with over 50 major surveying equipment dealers globally, facilitating the adoption of its technology. The WingtraOne can be operated using WingtraPilot software, enabling users to collect survey-grade aerial data that can be transformed into two-dimensional maps and three-dimensional models, thereby enhancing monitoring and inspection capabilities in sectors such as construction, mining, and environmental management.

Sensius B.V., founded in 2015 and based in Rotterdam, Netherlands, specializes in developing advanced thermotherapy systems for treating head and neck cancers. The company's proprietary technology incorporates localized heating through an integrated microwave system, complemented by interactive software, which allows healthcare professionals to enhance traditional cancer treatments such as radiotherapy and chemotherapy. This innovative approach aims to improve patient outcomes and quality of life by mitigating the toxic effects commonly associated with standard therapies. Sensius has successfully treated seventy patients with its device, achieving a complete response rate of 81.8% at 12 weeks post-treatment. Currently, the company is working towards obtaining CE marking for its device, with significant interest from potential buyers, as it also plans to expand its application to other cancer types in the future.

Sensius B.V., founded in 2015 and based in Rotterdam, Netherlands, specializes in developing advanced thermotherapy systems for treating head and neck cancers. The company's proprietary technology incorporates localized heating through an integrated microwave system, complemented by interactive software, which allows healthcare professionals to enhance traditional cancer treatments such as radiotherapy and chemotherapy. This innovative approach aims to improve patient outcomes and quality of life by mitigating the toxic effects commonly associated with standard therapies. Sensius has successfully treated seventy patients with its device, achieving a complete response rate of 81.8% at 12 weeks post-treatment. Currently, the company is working towards obtaining CE marking for its device, with significant interest from potential buyers, as it also plans to expand its application to other cancer types in the future.

Valo Therapeutics is an immunotherapy company based in Oxford, United Kingdom, with an additional office in Helsinki, Finland. Founded in 2016, the company focuses on developing antigen-coated oncolytic viruses as therapeutic vaccines for cancer treatment. Its primary platform, PeptiCRAd, is an engineered human oncolytic adenovirus designed to stimulate a systemic anti-tumor T cell response. This innovative approach enables the conversion of oncolytic adenoviruses into targeted, tissue-specific cancer vaccines without the need for multiple genetically modified viruses. Additionally, Valo Therapeutics is working on other strategies, such as PeptiENV, to enhance therapeutic responses to enveloped oncolytic viruses across various cancer types. By utilizing tumor-specific peptides, the company aims to elicit a robust adaptive immune response, potentially providing lasting immunity against multiple cancers and improving patient outcomes.

Kvantify, founded in 2022 and headquartered in Copenhagen, Denmark, specializes in quantum computing management software aimed at addressing complex computational challenges across various sectors, including life sciences, financial services, and logistics. The company's platform focuses on enhancing drug discovery processes by employing proprietary physics-based methods to improve the quality of compounds tested in laboratories. By providing advanced computational drug technology, Kvantify enables life sciences companies to accelerate small molecule research and obtain actionable results that significantly impact their operations.

N2 Applied is a Norwegian technology company focused on revolutionizing fertilizer production for farmers. Operating from its headquarters in Oslo/Asker and with a test center in Svene, Norway, along with branches in the Netherlands and the UK, N2 Applied has developed an innovative technology that allows for the local production of fertilizer using liquid organic substrates like slurry or digestate, combined with air and electricity. This process enhances nitrogen content while preventing ammonia loss and reducing emissions, thus promoting a more sustainable farming approach. By utilizing plasma reactors, the company enables farmers to recycle livestock manure into environmentally friendly fertilizer, lowering production costs and increasing crop yields. N2 Applied's scalable solution aims to streamline the fertilizer supply chain, minimizing reliance on fossil fuel-based chemical fertilizers and contributing to on-farm reductions in methane and ammonia emissions.

Ganymed Robotics SAS is a medical device company based in Paris, France, established in 2018. The company specializes in developing advanced robotics technologies and software aimed at enhancing surgical precision in orthopedic procedures, particularly focusing on knee replacement surgeries. Its innovative therapeutic device is designed to improve patient outcomes and streamline the surgical process, enabling orthopedic surgeons to reduce operating times and enhance their overall experience. By integrating robotics into surgical practices, Ganymed Robotics aims to advance the efficiency of care delivery in the orthopedic field.

Daze is an engineering startup focused on creating innovative solutions for electric vehicle charging. Its flagship product, DazePlug, is an automatic charging device that utilizes smart charging ecosystems and energy management systems. This technology enables automatic inductive charging, significantly reducing the time required to charge electric vehicles while eliminating the need for manual handling of cables. DazePlug features a retrofit design that is both waterproof and dustproof, ensuring durability and ease of use. By simplifying the charging process, Daze aims to enhance user experience and convenience for electric vehicle owners.

iThera Medical specializes in advanced biomedical imaging technology, focusing on photonic molecular imaging. Founded in 2010 as a spin-off from the Helmholtz Zentrum Muenchen, the company collaborates with this research center to enhance its proprietary Multi-Spectral Optoacoustic Tomography (MSOT) technology. This innovative approach provides real-time visualization of anatomical, functional, and molecular information within living tissue, which aids in the detection of tumors and inflammatory diseases. By enabling non-invasive diagnostic capabilities, iThera Medical supports both preclinical and clinical applications, offering significant advancements in medical imaging and patient care.

Resistell AG, founded in 2018 and located in Muttenz, Switzerland, develops and markets a diagnostic device for antibiotic susceptibility testing. Utilizing nanomotion technology, the device detects the movement of living bacterial cells to assess their resistance to antibiotics, offering a rapid alternative to traditional culture-based methods. This innovative approach allows for timely and accurate identification of the most effective antibiotics for patients, addressing the growing challenge of antibiotic resistance.

CARMAT is a France-based medtech company that specializes in the development and manufacture of bioprosthetic artificial hearts aimed at treating patients with severe heart failure. Founded in 2008 and located in Vélizy-Villacoublay, the company produces biocompatible and auto-regulated total artificial hearts that closely mimic the human heart's functionality. These devices are designed for individuals experiencing chronic terminal heart failure classified as NYHA class IV or those suffering from acute terminal heart failure following a major heart attack. CARMAT's innovative solutions target patients who are not suitable for heart transplantation and have exhausted other treatment options, providing a reliable new therapeutic alternative. In addition to the artificial hearts, CARMAT also develops the associated power supply and control systems, including remote diagnosis capabilities.

INBRAIN Neuroelectronics is a medical device company based in Barcelona, Spain, that specializes in developing graphene-based neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. Founded in 2019, the company offers the world's first brain-computer interface (BCI) therapeutics platform, which integrates precise BCI decoding with micrometric modulation to provide adaptive and personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. Its technology enables continuous real-time monitoring and autonomous adjustments to therapy, enhancing therapeutic outcomes while reducing side effects. INBRAIN is also engaged in strategic collaborations, including with Merck KGaA, to expand its innovative solutions into peripheral nerve and systemic disease applications, thereby advancing the field of neurotechnology and bioelectronics.

Nano4Imaging GmbH, founded in 2011 and based in Aachen, Germany, specializes in the development and production of contrast agents and devices designed for in-vivo imaging of medical implants and minimal invasive devices, such as catheters and guidewires. The company offers products like MRWire EmeryGlide, a guide wire compatible with magnetic resonance imaging (MRI), and the MagnaFy series, which includes coatings that enhance visibility under MRI, computed tomography (CT), and X-ray imaging. These innovations facilitate medical interventions and therapies, particularly in the treatment of cardiovascular diseases and during radiotherapy, allowing for precise monitoring of medical devices during procedures. By leveraging nanotechnology, Nano4Imaging aims to enhance diagnostic imaging capabilities for healthcare professionals.

CARMAT is a France-based medtech company that specializes in the development and manufacture of bioprosthetic artificial hearts aimed at treating patients with severe heart failure. Founded in 2008 and located in Vélizy-Villacoublay, the company produces biocompatible and auto-regulated total artificial hearts that closely mimic the human heart's functionality. These devices are designed for individuals experiencing chronic terminal heart failure classified as NYHA class IV or those suffering from acute terminal heart failure following a major heart attack. CARMAT's innovative solutions target patients who are not suitable for heart transplantation and have exhausted other treatment options, providing a reliable new therapeutic alternative. In addition to the artificial hearts, CARMAT also develops the associated power supply and control systems, including remote diagnosis capabilities.

ABCDx SA is a Swiss company founded in 2014 that specializes in the development, validation, and application of biomarker tests for brain injury treatment. The company focuses on creating biomarker panels designed to identify and diagnose patients at risk for severe long-term complications resulting from conditions such as traumatic brain injuries, strokes, and post-stroke infections. The founders are prominent researchers from the University of Geneva and the Vall d’Hebron Research Institute, bringing significant expertise in biomarker discovery and clinical application. They are complemented by a third founder with extensive experience in the diagnostic and pharmaceutical industries, enhancing the company’s capacity to innovate in brain health diagnostics.

Precisis is a medical technology company based in Heidelberg, Germany, founded in 2004. The company focuses on developing innovative medical devices aimed at treating epilepsy and enhancing patients' quality of life. Their flagship product involves a device that delivers individualized brain stimulation through a surgical procedure. This device is precisely positioned beneath the scalp over the epileptic origin in the brain, allowing for targeted therapeutic currents to be directed at specific areas without direct contact with the brain. This approach aims to provide deep and focused stimulation to effectively manage epilepsy.

INBRAIN Neuroelectronics is a medical device company based in Barcelona, Spain, that specializes in developing graphene-based neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. Founded in 2019, the company offers the world's first brain-computer interface (BCI) therapeutics platform, which integrates precise BCI decoding with micrometric modulation to provide adaptive and personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. Its technology enables continuous real-time monitoring and autonomous adjustments to therapy, enhancing therapeutic outcomes while reducing side effects. INBRAIN is also engaged in strategic collaborations, including with Merck KGaA, to expand its innovative solutions into peripheral nerve and systemic disease applications, thereby advancing the field of neurotechnology and bioelectronics.

Dimenco B.V. is a Netherlands-based company that specializes in 3D autostereoscopic technology, offering a range of products and services for both professional and consumer markets. Founded in 2010 and operating as a subsidiary of Top Wise International Enterprise Limited, Dimenco develops 3D displays that allow viewers to see different images without the use of special glasses. Their offerings include autostereoscopic displays, software, content conversion, and consultancy services. The company also provides tools such as the DirectX Visualizer and OpenGL Visualizer, which enable users to experience 3D applications on its displays, and the Dimenco 3D Player for playing 3D video clips. By utilizing a lenticular overlay on LCDs, Dimenco's technology enhances visual experiences, bridging the gap between excitement and reality for users.

Nexdot specializes in the synthesis, production, and application of advanced semiconductor nanocrystals known as Quantum Dots (QDs), with a focus on nanoplatelets—two-dimensional nanosheet Quantum Dots that exhibit enhanced properties. Founded as a spin-off from a leading academic laboratory in Paris, Nexdot leverages over a decade of research in nanomaterials to create proprietary materials with controlled shape and composition. These innovations are poised to transform various industries, including displays, lighting, energy storage, detectors, and bio-imaging. Additionally, Nexdot is developing quantum pearl encapsulation technology to enhance the integration of quantum plates into existing production processes, thereby ensuring compliance with environmental regulations. The company is comprised of a dynamic team of skilled scientists and seasoned executives, dedicated to advancing innovation in the field of nanotechnology.

ScanTrust SA is a Swiss company that specializes in a cloud-based IoT platform aimed at enhancing product and packaging security through unique identifiers. Founded in 2014 and with operations in cities such as Shanghai, Singapore, and Bangkok, ScanTrust provides a suite of tools including a printer portal for packaging partners to integrate secure codes into their processes, and Scan-data, an online portal for real-time business intelligence and supply chain insights. Additionally, the platform enables product authentication and supply chain traceability using QR codes, which can be verified through mobile applications. By protecting brands and facilitating consumer engagement, ScanTrust helps companies navigate the complexities of selling physical products in a connected market.

Alesi Surgical Ltd. specializes in the development and commercialization of laparoscopic surgical smoke handling systems aimed at enhancing the safety and outcomes of surgical procedures. Founded in 2009 and based in Cardiff, United Kingdom, the company emerged as a spin-out from the Welsh Institute for Minimal Access Therapy, benefiting from direct access to experienced surgeons and surgical trainers. Alesi Surgical's innovative products are designed to be portable and applicable in both laparoscopic and robot-assisted surgeries. Utilizing electrostatic precipitation technology, these tools effectively eliminate surgical smoke, ensuring a clear visual field during procedures. Alesi Surgical distributes its products to hospitals across Europe, the Middle East, New Zealand, and Australia.

FOx Biosystems is a biotechnology company focused on enhancing biomolecular interaction analysis for life science research and industry. Founded in 2017 by Filip Delport and Jeroen Lammertyn, and based in Temse, Oost-Vlaanderen, Belgium, the company specializes in developing custom applications, including probes and devices, to support various research needs. FOx Biosystems employs real-time, label-free analysis technology that offers significant advantages over traditional biomolecular analysis tools, such as ease of use, speed, and cost-effectiveness. This technology enables healthcare companies and researchers to obtain high-quality biomolecular data, including concentration measurements, affinity data, and kinetic data, ultimately aiming to transform the life sciences sector.

ELEM Biotech SL is a biomedical software company based in Barcelona, Spain, that specializes in creating virtual human beings using advanced mathematical modeling and cloud computing. Founded in 2018 by researchers from the Barcelona Supercomputing Center, ELEM has developed Alya Red, a suite of simulation tools designed for the medical device and pharmaceutical industries. Utilizing a Software-as-a-Service model, Alya Red allows for the simulation of cardiovascular and respiratory systems on virtual patients. By integrating high-performance computing, computational biomechanics, and data analysis, ELEM's technology enables biomedical companies and clinicians to improve diagnoses, plan treatments, and optimize drug delivery and medical devices.

IonKraft, a German technology company, specializes in plasma coating solutions for multi-material plastic containers. Their innovative plasma-enhanced chemical vapor deposition process enables recyclability in packaging for various industries, including food, pharmaceuticals, and chemicals. By promoting material reduction and reuse, IonKraft aims to enhance performance and lower costs, backed by funding from the German Federal Ministry for Economic Affairs and Energy.

Deep Render Ltd. is a London-based AI start-up that originated from the Department of Computing at Imperial College London. The company specializes in developing advanced media compression algorithms using proprietary and patented technology grounded in machine learning research. Its innovative approach focuses on deep learning, density estimation, and unsupervised learning, resulting in state-of-the-art Biological Image Compression that offers at least a 50% efficiency gain over existing standards. Deep Render's technology is notable for being the first AI-based codec capable of real-time video playback, allowing for significant market expansion and cost reduction for users.

Cailabs is a French deep tech company based in Rennes, specializing in the design and production of photonic solutions that optimize the use of light in various applications. The company focuses on light shaping components, including mode multiplexers and converters for fiber optic networks, utilizing its patented Multi-Plane Light Conversion (MPLC) technology to reshape both single-mode and multi-mode coherent beams. Cailabs offers products tailored for telecommunications research and development, as well as multi-mode fiber link upgrades for enterprise networks. Additionally, the company provides integrated solutions for the industrial laser sector, such as laser beam shapers and combiners for material processing, and mode-selective multiplexers for EDFA arrays. Founded in 2013, Cailabs aims to address critical industrial challenges through its innovative optical components and expertise.

Creating transformative change in urban mobility, making our cities cleaner and more enjoyable. We first focus on urban logistics, moving goods around the city in ways that are sustainable, efficient and cost-effective. Our vehicle and its modular platform system, with easily swappable modular units, meets the needs of city logistics. From moving food to flowers to furniture, the possibilities are endless. ONO’s founders, pioneer in e-mobility solutions, Beres Seelbach, former head of design at Mercedes and Volkswagen, Murat Günak, and light electric vehicle expert and engineer, Philipp Kahle, sought to rethink and reshape modern urban transportation. They put together a forward-thinking group of designers, engineers and creative thinkers who shared their vision of transforming urban mobility. ONO is a Berlin-based e-mobility company introducing a whole new category of emissions-free vehicle: the Pedal Assisted Transporter (PAT), combining the flexibility of a bicycle with the capacity and durability of a van. We offer environmentally friendly urban logistics solutions designed and optimised for cities of today.

ROSI is a company based in Grenoble, France, that focuses on innovative recycling and revalorization technologies tailored for the photovoltaic industry. The company specializes in recovering ultra-pure silicon and other valuable metals that are typically lost during the manufacturing of photovoltaic cells and at the end of solar panel life cycles. By valorizing silicon waste generated during the solar wafer slicing process, as well as fine silicon particles lost during production, ROSI aims to make the production of photovoltaic modules more sustainable and cost-effective.

APIX Analytics, founded in 2014 and headquartered in Grenoble, France, specializes in developing and marketing advanced gas analyzer systems. The company focuses on creating miniaturized multigas analyzers that leverage nano-silicon technology to enhance chemical analysis across industrial, environmental, and security applications. By integrating traditional analytical processes such as gas sampling, injection, and separation of complex mixtures, APIX Analytics improves the specificity, detection, identification, and quantification of gas compounds. This innovative approach aims to support clients in meeting safety and quality standards in various sectors, particularly in renewable development.

Positrigo AG is a Swiss company based in Zurich that specializes in the development, production, and sales of dedicated brain positron emission tomography (PET) scanners. Founded in 2018, Positrigo focuses on making functional brain imaging accessible for early detection of neurodegenerative diseases, particularly Alzheimer's disease. The company provides advanced scanning solutions that aid in diagnostics, treatment monitoring, and the development of new therapies for conditions such as Lewy body dementia, vascular dementia, and frontotemporal dementia. By enabling early diagnosis in an affordable manner, Positrigo aims to improve patient outcomes and support healthcare professionals in managing these complex medical conditions.

Ostoform Limited is a medical device company based in Dublin, Ireland, focused on improving skin health for individuals with ostomies. Founded in 2016 as a spin-out from the University of Limerick, Ostoform develops patented technologies aimed at managing and reducing skin complications associated with ostomies. The company's primary products include a mouldable seal that fits securely around the stoma and FLOWASSIST, which directs stoma output away from the skin. By effectively guiding the corrosive output into the ostomy bag, these products help prevent skin irritation and swelling, enhancing patient comfort and quality of life. Ostoform aims to become a global leader in the ostomy skin health market, leveraging its innovative solutions to address the needs of ostomy patients.

Celeris Therapeutics is an AI-driven drug discovery company focused on developing proximity-inducing compounds (PICs), particularly PIC degraders, to address diseases with significant unmet medical needs, including Parkinson's disease and various cancers. The company utilizes its proprietary Celeris One platform, which employs structure-based geometric deep learning to enhance the design and development of degraders. This platform aids in the prioritization of specific E3 ligases, the design of linkers, and the selection of the most promising compounds for synthesis. Additionally, Celeris Therapeutics operates an automated laboratory that rapidly generates experimental data for further optimization. The company collaborates with pharmaceutical and biotech firms to co-develop small-molecule degrader therapies across various therapeutic areas while also building its own drug pipeline. Celeris Therapeutics maintains offices in Menlo Park, California, and Graz, Austria.

Fineheart is a France-based medical device company that specializes in innovative technologies aimed at addressing cardiovascular diseases. The company is developing an implantable cardiac device that is wirelessly powered and fully implantable, designed to provide mechanical circulatory support. This novel device optimizes cardiac output while preserving the heart's natural contractility, thereby enabling patients with heart failure to restore normal cardiac function and improve their quality of life. Fineheart's focus on advanced medical solutions positions it as a key player in the evolving landscape of cardiovascular care.

Fineheart is a France-based medical device company that specializes in innovative technologies aimed at addressing cardiovascular diseases. The company is developing an implantable cardiac device that is wirelessly powered and fully implantable, designed to provide mechanical circulatory support. This novel device optimizes cardiac output while preserving the heart's natural contractility, thereby enabling patients with heart failure to restore normal cardiac function and improve their quality of life. Fineheart's focus on advanced medical solutions positions it as a key player in the evolving landscape of cardiovascular care.

Tilkal is a Paris-based company founded in 2017 that specializes in supply chain traceability through its innovative software platform. This platform utilizes a B2B blockchain network to facilitate secure and verifiable data sharing among various supply chain stakeholders. Tilkal’s software captures traceability data from physical products in a ledger, enabling companies to obtain real-time insights into their supply chains. Customers leverage the platform to address critical questions regarding product location, sourcing risks, ESG commitments, and compliance verification. Notable clients include Danone, Daher, Joone, and the Responsible Mica Initiative, among others. The Tilkal network comprises over 70 independent nodes, with nearly 700 companies actively participating to share and analyze data, thereby enhancing the resilience, sustainability, and ethical standards of their supply chains.

AugmedIT B.V. is a medical software company based in Amsterdam, the Netherlands, founded in 2018. The company focuses on developing augmented and mixed reality tools that enhance surgical procedures by enabling surgeons to create holograms of patients. AugmedIT specializes in applications related to neurosurgery, medical education, and holographic visualization, as well as neuronavigation. Through its innovative technology, the company aims to improve surgical precision and training in the medical field.

Tilkal is a Paris-based company founded in 2017 that specializes in supply chain traceability through its innovative software platform. This platform utilizes a B2B blockchain network to facilitate secure and verifiable data sharing among various supply chain stakeholders. Tilkal’s software captures traceability data from physical products in a ledger, enabling companies to obtain real-time insights into their supply chains. Customers leverage the platform to address critical questions regarding product location, sourcing risks, ESG commitments, and compliance verification. Notable clients include Danone, Daher, Joone, and the Responsible Mica Initiative, among others. The Tilkal network comprises over 70 independent nodes, with nearly 700 companies actively participating to share and analyze data, thereby enhancing the resilience, sustainability, and ethical standards of their supply chains.

IRUBIS GmbH, founded in 2017 and based in Munich, Germany, specializes in the development of mid-infrared (MIR) spectrometers and attenuated total reflection (ATR) crystals. The company focuses on enhancing Fourier transform infrared (FTIR) spectroscopy to improve the analysis of protein-based drugs. Its innovative measurement systems enable real-time bioreactor monitoring, allowing for the online assessment of glucose and lactate levels without contamination risks. IRUBIS also produces a range of ATR crystals, including single-reflection and signal-enhanced varieties, aimed at advancing industry standards for bioprocess monitoring. The company’s technology supports both upstream and downstream bioprocessing, facilitating metabolite monitoring and the detection of target proteins and contaminants through machine-learning evaluation software.

IRUBIS GmbH, founded in 2017 and based in Munich, Germany, specializes in the development of mid-infrared (MIR) spectrometers and attenuated total reflection (ATR) crystals. The company focuses on enhancing Fourier transform infrared (FTIR) spectroscopy to improve the analysis of protein-based drugs. Its innovative measurement systems enable real-time bioreactor monitoring, allowing for the online assessment of glucose and lactate levels without contamination risks. IRUBIS also produces a range of ATR crystals, including single-reflection and signal-enhanced varieties, aimed at advancing industry standards for bioprocess monitoring. The company’s technology supports both upstream and downstream bioprocessing, facilitating metabolite monitoring and the detection of target proteins and contaminants through machine-learning evaluation software.

Vatorex AG, founded in 2016 and based in Winterthur, Switzerland, specializes in developing electronic solutions for beekeeping, specifically targeting the varroa mite, a significant threat to honey bee health. The company offers a range of products, including the Varroa Solution, a heat treatment system that effectively eliminates varroa mites while preserving the bees. Additionally, Vatorex provides the Full Hive Kit, which enables real-time monitoring and data collection for hive management, and the Hive Manager mobile application, designed for organizing hive-related information. By focusing on hyperthermic treatment that exploits the different temperature tolerances of bees and mites, Vatorex aims to enhance the health and sustainability of bee populations. The company markets its innovative solutions online, contributing to modern beekeeping practices.

Born from the MRCLEAN trial, NICO.LAB was founded in 2015 as a spin-off from the Amsterdam University Medical Center. Our research background continues to drive our way of thinking. The team consists of researchers, developers and experienced medical specialists to ensure we align with our clients needs. We believe connecting human & artificial intelligence will revolutionize emergency care. Our cloud-based solution, StrokeViewer, automatically analyses brain CT scans and gives results within minutes. StrokeViewer empowers physicians in the emergency setting to provide patients with the right treatment in time.

ELEM Biotech SL is a biomedical software company based in Barcelona, Spain, that specializes in creating virtual human beings using advanced mathematical modeling and cloud computing. Founded in 2018 by researchers from the Barcelona Supercomputing Center, ELEM has developed Alya Red, a suite of simulation tools designed for the medical device and pharmaceutical industries. Utilizing a Software-as-a-Service model, Alya Red allows for the simulation of cardiovascular and respiratory systems on virtual patients. By integrating high-performance computing, computational biomechanics, and data analysis, ELEM's technology enables biomedical companies and clinicians to improve diagnoses, plan treatments, and optimize drug delivery and medical devices.

Dimenco B.V. is a Netherlands-based company that specializes in 3D autostereoscopic technology, offering a range of products and services for both professional and consumer markets. Founded in 2010 and operating as a subsidiary of Top Wise International Enterprise Limited, Dimenco develops 3D displays that allow viewers to see different images without the use of special glasses. Their offerings include autostereoscopic displays, software, content conversion, and consultancy services. The company also provides tools such as the DirectX Visualizer and OpenGL Visualizer, which enable users to experience 3D applications on its displays, and the Dimenco 3D Player for playing 3D video clips. By utilizing a lenticular overlay on LCDs, Dimenco's technology enhances visual experiences, bridging the gap between excitement and reality for users.

ABCDx SA is a Swiss company founded in 2014 that specializes in the development, validation, and application of biomarker tests for brain injury treatment. The company focuses on creating biomarker panels designed to identify and diagnose patients at risk for severe long-term complications resulting from conditions such as traumatic brain injuries, strokes, and post-stroke infections. The founders are prominent researchers from the University of Geneva and the Vall d’Hebron Research Institute, bringing significant expertise in biomarker discovery and clinical application. They are complemented by a third founder with extensive experience in the diagnostic and pharmaceutical industries, enhancing the company’s capacity to innovate in brain health diagnostics.

Circu Li-Ion is a Luxembourg-based start-up focused on automated battery disassembly and diagnostics, aimed at enhancing the remanufacturing, reuse, and recycling of lithium-ion batteries. The company's innovative platform features three main components: a battery library, an application layer, and robotic disassembly systems. These systems significantly reduce costs by limiting manual labor and indirect expenses, achieving a 47% cost reduction overall. With 67% robot autonomy, Circu Li-Ion minimizes human intervention during disassembly, thereby increasing safety and ensuring a 95% component recovery rate. This process not only preserves the material value of batteries but also helps clients capitalize on the potential for upcycling components, addressing labor shortages while contributing positively to environmental goals.

Nexdot specializes in the synthesis, production, and application of advanced semiconductor nanocrystals known as Quantum Dots (QDs), with a focus on nanoplatelets—two-dimensional nanosheet Quantum Dots that exhibit enhanced properties. Founded as a spin-off from a leading academic laboratory in Paris, Nexdot leverages over a decade of research in nanomaterials to create proprietary materials with controlled shape and composition. These innovations are poised to transform various industries, including displays, lighting, energy storage, detectors, and bio-imaging. Additionally, Nexdot is developing quantum pearl encapsulation technology to enhance the integration of quantum plates into existing production processes, thereby ensuring compliance with environmental regulations. The company is comprised of a dynamic team of skilled scientists and seasoned executives, dedicated to advancing innovation in the field of nanotechnology.

Tozero, founded in July 2022 in Munich, Germany, by Sarah Fleischer and Dr. Ksenija Milicevic Neumann, focuses on developing technology for recycling lithium-ion batteries. The company aims to create a scalable machine that recovers essential materials such as lithium, nickel, cobalt, graphite, and manganese in an environmentally sustainable manner. By facilitating the recovery of these critical materials, Tozero enables industries to reintegrate fresh raw materials back into the supply chain, thereby supporting broader decarbonization efforts.

AMT Medical B.V., founded in 2015 and based in Ede, the Netherlands, specializes in developing innovative devices for heart bypass surgery. The company has created the AMT Heart Bypass System, which utilizes the ELANA bypass technique, originally developed by neurosurgeon Prof. Dr. C.A.F. Tulleken and his team. This minimal invasive approach aims to enhance traditional heart bypass procedures by making them faster, safer, and less invasive, ultimately improving patient outcomes and recovery times. The AMT Heart Bypass System has completed its development and production processes, as well as all pre-clinical trials. A clinical multi-center trial is set to begin in late 2019 or early 2020, marking a significant step in bringing this advanced technology to the medical community.

Dawn Aerospace is a company that designs and manufactures reusable spacecraft and non-toxic propulsion systems for satellites. Founded in 2016 and headquartered in Delft, Netherlands, with facilities in Auckland, New Zealand, Dawn Aerospace focuses on developing same-day reusable launch vehicles that integrate with conventional aircraft, allowing for frequent and routine launches similar to commercial aviation. Their product line includes the MK-1, MK-2, MK-3, and MK-4 vehicles. In addition, the company offers high-performance propulsion systems that replace toxic fuels, like hydrazine, with safer alternatives, enhancing capabilities for satellites of various sizes, including CubeSats. By combining these technologies, Dawn Aerospace aims to create a scalable and environmentally friendly architecture for satellite delivery, positioning, and return.

Ganymed Robotics SAS is a medical device company based in Paris, France, established in 2018. The company specializes in developing advanced robotics technologies and software aimed at enhancing surgical precision in orthopedic procedures, particularly focusing on knee replacement surgeries. Its innovative therapeutic device is designed to improve patient outcomes and streamline the surgical process, enabling orthopedic surgeons to reduce operating times and enhance their overall experience. By integrating robotics into surgical practices, Ganymed Robotics aims to advance the efficiency of care delivery in the orthopedic field.